iShares Genomics Immunology and ETF News

This article provides a monthly dashboard with aggregate industry metrics in the healthcare sector. Fast facts on IDNA, a thematic and volatile biotech ETF. We conclude with 10 healthcare stocks cheap

Good Morning, VettaFi Voices! Disruptive innovation is a popular topic, and it encompasses everything from bitcoin and cryptocurrency to electric vehicles to artificial intelligence.

I rate IDNA a Hold due to its focus on biotech stocks with long-term growth potential in a rapidly growing healthcare industry. Despite impressive growth since its inception in 2019, IDNA has experien

Genomic revolution and pharmacogenomics have strong growth prospects that may enable the iShares Genomics Immunology and Healthcare ETF biotech portfolio to generate supernormal growth. In order to en

A decade ago, when the ROBO Global Robotics & Automation Index ETF (ROBO) launched, the U.S. thematic ETF market was nascent, with only a handful of products and minimal assets. However, at the end of

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

Pharmaceuticals and biotechnology still look attractive. Healthcare providers are close to their baseline in both valuation and quality.

Cathie Wood, famous for the success of Ark Investment???s winning products, had faced a miserable fate in 2022.

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Healthcare equipment and life science tools are overvalued by about 25% regarding the same metr

The category represents a rapidly growing portion of the issuer's lineup.

Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic

Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfize

Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued.

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.